Effect of cinnamon on liver disease

Phase 2

• Conditions: on-alcoholic steatohepatitis.; nonalcoholic steatohepatitis

• Registration Number: IRCT2015062115587N9
• Lead Sponsor: Vice –Chancellor of Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Inclusion criteria of the study:
ALT level higher than 65U/L; Diagnosed fatty liver in ultrasonography; No alcohol and drug abuse; No history of chemotherapy in the past years; No history of other chronic liver diseases such as hepatitis B and hepatitis C, cirrhosis, bile diseases, autoimmune diseases, cancer and any genetic disorder that effects liver function such as Wilson’s disease; No history of lipid-lowering drug use; No pregnancy and breast-feeding; No use of vitamin E supplements; No use of drugs that caused fatty liver, like tetracycline, vitamin A, methotrexate, amiodarone, tamoxifen, etc.; No history of use of hepatotoxic drugs in the last 6 months; No long-term use of herbal drugs
Exclusion criteria:
If the patient indicates hypersensitivity reactions to cinnamon, becomes pregnant or not interested, and also if the level of liver enzymes rises at the end of the forth week due to cinnamon consumption, the patient will be excluded from the study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in ALT serum level. Timepoint: Before intervention, at the end of the fourth week of intervention, at the end of the eighth week of intervention. Method of measurement: Blood test and laboratory kits.;Reduction in AST serum level. Timepoint: Before intervention, at the end of the fourth week of intervention, at the end of the eighth week of intervention. Method of measurement: Blood test and laboratory kits.

Secondary Outcome Measures

Name	Time	Method
ipid profile improvement. Timepoint: Before intervention, at the end of the fourth week of intervention, at the end of the eighth week of intervention. Method of measurement: Blood test and laboratory kits.